The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis
Open accessAbstract
Background: Extended, more effective breast cancer treatments have increased the prevalence of long-term survivors. We investigated the risk of late breast cancer recurrence (BCR), 10 years or more after primary diagnosis, and associations between patient and tumor characteristics at primary diagnosis and late BCR up to 32 years after primary breast cancer diagnosis. Methods: Using the Danish Breast Cancer Group clinical database, we identified all women with an incident early breast cancer diagnosed during 1987-2004. We restricted to women who survived 10 years without a recurrence or second cancer (10-year disease-free survivors) and followed them from 10 years after breast cancer diagnosis date until late recurrence, death, emigration, second cancer, or December 31, 2018. We calculated incidence rates per 1000 person-years and cumulative incidences for late BCR, stratifying by patient and tumor characteristics. Using Cox regression, we calculated adjusted hazard ratios for late BCR accounting for competing risks. Results: Among 36 924 women with breast cancer, 20 315 became 10-year disease-free survivors. Of these, 2595 developed late BCR (incidence rate = 15.53 per 1000 person-years, 95% confidence interval = 14.94 to 16.14; cumulative incidence = 16.6%, 95% confidence interval = 15.8% to 17.5%) from year 10 to 32 after primary diagnosis. Tumor size larger than 20 mm, lymph node–positive disease, and estrogen receptor–positive tumors were associated with increased cumulative incidences and hazards for late BCR. Conclusions: Recurrences continued to occur up to 32 years after primary diagnosis. Women with high lymph node burden, large tumor size, and estrogen receptor–positive tumors had increased risk of late recurrence. Such patients may warrant extended surveillance, more aggressive treatment, or new therapy approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
The Danish National Patient Registry: a review of content, data quality, and research potential
Schmidt, M., Schmidt, S. A. J., Sandegaard, J. L., Ehrenstein, V., Pedersen, L., & Sørensen, H. T. (2015) · Clinical Epidemiology · doi:10.2147/clep.s91125 · Cited by 4,769
The Danish Civil Registration System as a tool in epidemiology
Schmidt, M., Pedersen, L., & Sørensen, H. T. (2014) · European Journal of Epidemiology · doi:10.1007/s10654-014-9930-3 · Cited by 3,441
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., Bergh, J., Dowsett, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701830 · Cited by 1,822
The Danish Register of Causes of Death
Helweg-Larsen, K. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811399958 · Cited by 1,732
Schmidt, M., Schmidt, S. A. J., Adelborg, K., Sundbøll, J., Laugesen, K., Ehrenstein, V., & Sørensen, H. T. (2019) · Clinical Epidemiology · doi:10.2147/clep.s179083 · Cited by 1,379
Research works printed but not linked: 12
- Pachmann, 2011, Tumor cell seeding during surgery—possible contribution to metastasis formations, Cancers (Basel), 3, 2540, 10.3390/cancers3022540 · doi:10.3390/cancers3022540
- Mamby, 1993, Metastatic breast cancer 39 years after primary treatment, Wis Med J, 92, 567
- Tashima, 2014, A case of local recurrence developing thirty-nine years after mastectomy for breast cancer, Gan To Kagaku Ryoho, 41, 357
- Kostev, 2018, 20-year risk of breast cancer recurrence, Breast Cancer Res Treat, 168, 765, 10.1007/s10549-017-4636-3 · doi:10.1007/s10549-017-4636-3
- Jensen, 2003, Validity and representativity in the Danish Breast Cancer Cooperative Group--a study on protocol allocation and data validity from one county to a multi-centre database, Acta Oncol Stockh Oncol, 42, 179, 10.1080/02841860310000737 · doi:10.1080/02841860310000737
- Pedersen, 2020, Validation of an algorithm to ascertain late breast cancer recurrence using Danish Medical Registries, Clin Epidemiol, 12, 1083, 10.2147/CLEP.S269962 · doi:10.2147/clep.s269962
- Christiansen, 2008, Recurrence pattern and prognosis in low-risk breast cancer patients--data from the DBCG 89-A programme, Acta Oncol Stockh Oncol, 47, 691, 10.1080/02841860802056594 · doi:10.1080/02841860802056594
- Talman, 2007, Invasive lobular breast cancer. Prognostic significance of histological malignancy grading, Acta Oncol, 46, 803, 10.1080/02841860601137397 · doi:10.1080/02841860601137397
- Anderson, 2018, Breast-cancer recurrence after stopping endocrine therapy, N Engl J Med, 378, 870, 10.1056/NEJMc1715968 · doi:10.1056/nejmc1715968
- Bodilsen, 2016, Importance of margin width in breast-conserving treatment of early breast cancer, J Surg Oncol, 113, 609, 10.1002/jso.24224 · doi:10.1002/jso.24224
- Giannakeas, 2019, A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy, Breast Cancer Res Treat, 177, 691, 10.1007/s10549-019-05334-5 · doi:10.1007/s10549-019-05334-5
- Narod, 2020, Late recurrences after estrogen receptor–positive breast cancer, JAMA Oncol, 6, 301, 10.1001/jamaoncol.2019.5579 · doi:10.1001/jamaoncol.2019.5579
Cited by
Lipsyc-Sharf, M., de Bruin, E. C., Santos, K., McEwen, R., Stetson, D., Patel, A., Kirkner, G. J., Hughes, M. E., Tolaney, S. M., Partridge, A. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00908 · Cited by 152
Sinclair, F., Gillanders, D., Rooney, N., Bonathan, C., Hendry, K., McLoone, P., & Hewitt, C. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-08179-3 · Cited by 9
Metadata
- Authors
- Pedersen, R. N., Esen, B. Ö., Mellemkjær, L., Christiansen, P., Ejlertsen, B., Lash, T. L., Nørgaard, M., & Cronin-Fenton, D.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-11-08
- Volume
- 114
- Issue
- 3
- Pages
- 391-399
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W3211678510
- Cited by
- 356
- References
- 31
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- DCF from the Danish Cancer Society (“Knæk Cancer” R147-A10100)
- Aarhus University
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis. https://app.cochat.ai/papers/10.1093/jnci/djab202
- The paper
- Pedersen, R. N., Esen, B. Ö., Mellemkjær, L., Christiansen, P., Ejlertsen, B., Lash, T. L., Nørgaard, M., & Cronin-Fenton, D. (2022). The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djab202
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.